Arcus Biosciences, Inc. Profile Avatar - Palmy Investing

Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 cl…

Biotechnology
US, Hayward [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Arcus Biosciences, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of RCUS's Analysis
CIK: 1724521 CUSIP: 03969F109 ISIN: US03969F1093 LEI: - UEI: -
Secondary Listings
RCUS has no secondary listings inside our databases.